Abstract: The present application discloses and claims liquid pharmaceutical compositions comprising bevirimat dimeglumine as a drug substance, methods of treatment comprising administering such compositions to a subject in need thereof, and the use of such compositions in the manufacture of medicaments.
Type:
Application
Filed:
March 25, 2010
Publication date:
August 26, 2010
Applicant:
Myriad Pharmaceuticals, Inc.
Inventors:
Jules S. Jacob, John Richards, John G. Augustine, Jaqueline S. Milea
Abstract: Provided herein are methods for treating the symptoms of and inflammation associated with gastroesophageal reflux disease (GERD) and other conditions. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Abstract: The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.
Type:
Application
Filed:
October 26, 2007
Publication date:
August 19, 2010
Applicant:
Ipsen Pharma S.A.S.
Inventors:
Roland Cherif-Cheikh, Anne-Paula De Sousa Delgado, Frédéric Lacombe, Laurence Lachamp, Didier Bourissou
Abstract: The present invention relates to an oral pharmaceutical preparation having an excellent capability of delivering a drug to colon, more specifically an oral pharmaceutical preparation for delivering a drug to colon and comprising a core comprising at least a pharmaceutically acceptable vehicle, an inner layer covering said core and comprising said drug, an intermediate layer covering said inner layer and comprising a cationic polymer soluble or swellable at a pH of not more than 6.6, and an outer layer covering said intermediate layer and comprising an anionic polymer soluble at a pH of not less than 7.0.
Abstract: A method of reducing the appearance of skin conditions associated with loss of skin tightness, skin firmness, or dark circles under the eyes with topical compositions comprising compounds of any of the Formulae I or Ia as described herein, is disclosed.
Type:
Application
Filed:
April 19, 2010
Publication date:
August 12, 2010
Inventors:
Bing Wang, Sekhar Bodupalli, Xiangfeng Li, Khalid Mahmood, Wei Zhang, Guy Miller
Abstract: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
Abstract: Syntheses of steroids such as 3-hydroxy-7?-methyl-21-[2?-methoxy-4?-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene citrate (“SR 16234”) and analogs thereof are provided, wherein 21-hydroxy-19-norpregna-4-en-3-one serves as a starting material or intermediate. The latter compound may be readily prepared from estrone-3-methyl ether. Certain intermediates in these syntheses also have value as therapeutic agents, for example in the treatment of prostate disorders such as prostatic cancer.
Type:
Grant
Filed:
August 9, 2004
Date of Patent:
August 10, 2010
Assignee:
SRI International
Inventors:
Richard H. Peters, Jyanwei Liu, John G. Johansson, Kenneth J. Ryan, Wan-Ru Chao, Masato Tanabe
Abstract: This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.
Type:
Application
Filed:
July 9, 2008
Publication date:
August 5, 2010
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
William R. Freeman, Michael J. Sailor, Lignyun Cheng
Abstract: The present invention provides an all-aqueous process and composition for production of silk biomaterials, e.g., fibers, films, foams and mats. In the process, at least one biocompatible polymer, such as poly(ethylene oxide) (PEO) (a well-documented biocompatible material), was blended with the silk protein prior to processing e.g., electrospinning. We discovered that this step avoids problems associated with conformational transitions of fibroin during solubilization and reprocessing from aqueous solution which lead to embrittled materials. Moreover, the process avoids the use of organic solvents that can pose problems when the processed biomaterials are exposed to cells in vitro or in vivo.
Type:
Application
Filed:
January 15, 2010
Publication date:
August 5, 2010
Applicants:
TRUSTEES OF TUFTS COLLEGE, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
David L. Kaplan, Hyoung-Joon Jin, Gregory Rutledge, Sergey Fridrikh
Abstract: A pharmaceutical composition for treatment of skin aging including a pharmaceutically effective amount of estriol; a pharmaceutically effective amount of estradiol; a pharmaceutically effective amount of hyaluronic acid; a pharmaceutically effective amount of green tea extract; and a pharmaceutically acceptable carrier is provided. In some embodiments, the composition further includes ascorbic acid, date palm extract, or a combination thereof. Also disclosed is a method for treating symptoms of skin aging and photoaging by administering a pharmaceutical composition having estriol, estradiol, hyaluronic acid, green tea extract, a pharmaceutically acceptable carrier and optionally, ascorbic acid and date palm extract. A method of promoting urogenital function is likewise provided wherein a pharmaceutical composition having estriol, estradiol, hyaluronic acid, and green tea extract is applied intravaginally.
Type:
Grant
Filed:
June 28, 2005
Date of Patent:
August 3, 2010
Assignee:
MCKA LLC
Inventors:
Stephanie N. McClellan, Ashton A. Kaidi
Abstract: Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell. Also provided are compounds useful for the treatment of Alexander disease in subjects at risk of or diagnosed with Alexander disease and methods for the identification of such compounds.
Type:
Application
Filed:
October 26, 2009
Publication date:
July 29, 2010
Inventors:
Albee Messing, Woosung Cho, Jon Scott Thorson, Randal D. Goff
Abstract: The present invention relates to the use of a steroid in the manufacture of a pharmaceutical composition for use in the therapeutic or prophylactic treatment of a hypertensive disorder of pregnancy (HDP) or fetal growth retardation, said treatment comprising administering to a female mammal a steroid selected from the group consisting of: substances represented by the following formula (formula I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors of such substances; and mixtures of one or more of the aforementioned substances and/or precursors.
Type:
Application
Filed:
July 14, 2008
Publication date:
July 22, 2010
Inventors:
Monique Visser, Herjan Jan Tijmen Coelingh Bennink
Abstract: The invention provides methods for decreasing or inhibiting poxvirus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with poxvirus infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of poxvirus infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).
Type:
Grant
Filed:
January 31, 2007
Date of Patent:
July 13, 2010
Assignees:
Brigham Young University, National Jewish Medical and Research Center
Abstract: A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.
Abstract: The invention provides tools, materials and related methods to surgically access the suprachoroidal space of an eye for the purpose of performing minimally invasive surgery or to deliver drugs to the eye. The invention provides a flexible microcannula or microcatheter device (11, 13) that may be placed into the suprachoroidal space (12, 14) through a small incision (12A) of the overlying tissues, maneuvered into the appropriate region of the space, and then activated to treat tissues adjacent to the distal tip of the device.
Type:
Application
Filed:
October 30, 2009
Publication date:
July 8, 2010
Inventors:
MICHAEL HEE, Stanley R. Conston, David J. Kupiecki, John R. McKenzie, Ronald Yamamoto, Michael Nash
Abstract: A method of achieving contraception in a woman which comprises administering orally to said woman an estroprogestative composition comprising nomegestrol acetate and an estrogen is provided.
Type:
Grant
Filed:
January 3, 2007
Date of Patent:
July 6, 2010
Assignee:
Laboratorie Theramek
Inventors:
Jacques Paris, Jean-Louis Thomas, Michel Lanquetin, Anny Lanquetin, legal representative, Jean-Philippe Lanquetin, legal representative
Abstract: Described herein are terpolymer compositions, kits comprising the compositions, implant devices comprising the compositions, and methods of making and using same, including point of use methods.
Type:
Application
Filed:
December 22, 2009
Publication date:
July 1, 2010
Inventors:
Kevin W. Burton, Howard Bowman, Danielle Biggs, Peter Markland
Abstract: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.
Abstract: The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder. A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.
Type:
Grant
Filed:
September 11, 2005
Date of Patent:
June 29, 2010
Assignees:
Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University
Abstract: A composition for bioactive agent release in vivo. The composition includes the bioactive agent in combination with a mixture of a first polymer component such as poly(butyl methacrylate) and a second polymer component such as poly(ethylene-co-vinyl acetate).
Type:
Application
Filed:
March 3, 2010
Publication date:
June 24, 2010
Applicant:
SurModics, Inc.
Inventors:
Stephen J. Chudzik, Timothy M. Kloke, Laurie R. Lawin, Ronald F. Ofstead, Ralph A. Chappa, Robert W. Hergenrother, Aron B. Anderson, Linh V. Tran
Abstract: Described herein are implantable composites, kits comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods.
Abstract: A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Cu(II) complex. The isoflavonoid or isoflavonoid mimetic may he non-fragmented steroidal hormone, such as progesterone which is structurally related to the isoflavone genistein, or a small molecule hormone mimetic, such as chromone. An illustrative non-fragmented steroidal embodiment is 17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,13,14,15, 16,17-tetradecahydrocyclopenta[a]phenanthren-3-thiosemicarbazone and its Cu(II) complex. Effective chromone analogs include the thiosemicarbazone and hydrazone analogs of 4-oxo-4H-chromene-3-carboxaldehyde and their Cu(IT) complexes.
Abstract: The present invention relates to a stable pharmaceutical composition of a poorly water-soluble drug with a view to increasing its solubility and bioavailability. The present invention relates to a solid dispersion of a poorly water-soluble drug.
Type:
Application
Filed:
March 10, 2008
Publication date:
June 17, 2010
Applicant:
Sandoz AG
Inventors:
Bharatrajan Ramaswami, Manisha Rajesh Patil, Aditi Das
Abstract: The present invention comprises small molecule inhibitors of cell proliferative conditions, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases. Thus, the present invention also comprises pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit cancer and treat, prevent, or inhibit the foregoing diseases.
Type:
Application
Filed:
December 9, 2009
Publication date:
June 10, 2010
Applicant:
ADVANCED LIFE SCIENCES, INC.
Inventors:
Ali Koohang, Aye Aye Mar, Erika Szotek, Ze-Qi Xu, David A. Eiznhamer, Michael T. Flavin
Abstract: The invention concerns a pharmaceutical composition comprises trimegestone optionally associated with an oestrogen, characterized in that it comprises a buffer solution whereof the pH, when it is introduced in the composition, ranging essentially between 2 and 5.5. The invention also concerns the methods for making such a composition and the primary package containing them.
Type:
Grant
Filed:
September 18, 2006
Date of Patent:
June 8, 2010
Assignee:
aventis pharma SA
Inventors:
Philippe Becourt, Robert Georges, Serge Segot Chicq
Abstract: A method of contraception in mammalian females, which method comprises the oral administration of an estrogenic component and a progestogenic component to a female of childbearing capability in an amount effective to inhibit ovulation, wherein the estrogenic component is selected from the group consisting of substances represented by the following formula (1) in which R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; and no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention concerns a pharmaceutical kit comprising oral dosage units that contain the aforementioned estrogenic component and/or a progestogenic component.
Type:
Grant
Filed:
May 23, 2002
Date of Patent:
June 8, 2010
Assignee:
Pantarhei Bioscience B.V.
Inventors:
Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka
Abstract: The invention relates to screening methods for determination of the risk of preterm delivery and/or pregnancy associated conditions. The methods involve detection of the level of one or more biomarkers in a biological sample from the patient. In particular, in embodiments of the invention there are provided methods for determining the risk of pre-eclampsia and other hypertensive disorders, and intrauterine growth retardation (IGUR).
Abstract: The present invention relates to a helically-shaped medicated veterinary system suitable for delivery of a drug to the vaginal cavity of a female non-human mammal and to a method of manufacture. The drug delivery system is helically-shaped and comprises a three layered polymer fibre. The polymer fibre comprises a polymer core, a polymer intermediate layer comprising a drug, and a polymer skin. The medicated system provides a controlled delivery of drug to the vaginal cavity of the mammal. The present invention also relates to a process of making the springs.
Type:
Application
Filed:
November 19, 2007
Publication date:
June 3, 2010
Inventors:
Marc-Antoine Driancourt, Wouter De Graff, Laura Buttafoco, Fabrice Payot, Harm Veenstra, René Willem Joris Voss
Abstract: Described are steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3?-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3?-ol or analogs thereof with tributylstannyl diazines. The compounds are potent inhibitors of human CYP17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds are useful for the treatment of human prostate cancer.
Abstract: Cosmetic substances having 1x×10?7 to 1×10?2 percent by weight of at least one steroid chosen from among certain 16-androstene and estrene steroids, and 0.1 to 30.0 percent by weight of at least one film-forming and/or solidifying polymers. Also disclosed is the use of those cosmetic substances for treating keratin fibers, particularly for temporarily deforming such fibers.
Abstract: The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder.
Type:
Grant
Filed:
November 19, 2004
Date of Patent:
May 4, 2010
Assignee:
CombinatoRx, Incorporated
Inventors:
Edward Roydon Jost-Price, Palaniyandi Manivasakam, Brendan Smith, Michael S. Slavonic, Benjamin A. Auspitz
Abstract: The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.
Abstract: The present invention is directed to methods of treatment of cystic fibrosis. The invention includes a method for treatment of cystic fibrosis in a patient by increasing the activity of sarcoendoplasmic reticulum calcium ATPase (SERCA) in a patient. More specifically, the step of increasing SERCA activity can include but is not limited to, administration of SERCA protein or its homologues, gene therapy to restore or enhance SERCA activity, or the administration of compounds stimulating the activity of endogenous SERCA. Reference herein to SERCA, can include in preferred embodiments, the isoform SERCA2, which is the principal lung isoform of SERCA. The present invention is based on the finding that SERCA2 (a calcium pump) is deficient (not 100%) in the lung epithelial cells of cystic fibrosis samples.
Abstract: The invention relates to a substance which lowers LDL cholesterol levels in serum and which is fat soluble ?-sitostanol fatty acid ester, and to a method for preparing and using the same. The substance can be taken orally as a food additive, food substitute or supplement. A daily consumption of the ?-sitostanol ester in an amount between about 0.2 and about 20 g/day has been shown to reduce the absorption of biliary and endogenic cholesterol.
Type:
Grant
Filed:
August 11, 2005
Date of Patent:
April 6, 2010
Assignee:
Raisio Nutrition Ltd.
Inventors:
Tatu Miettenen, Hannu Vanhanen, Ingmar Wester
Abstract: The present invention relates to an anoikis-inducing agent comprising a Tiarella polyphylla extract, a tiarellic acid compound isolated therefrom or a pharmaceutically acceptable salt thereof, which is specific to cancer cells expressing a tumor-associated antigen L6 or a homolog thereof. The Tiarella polyphylla extract, the tiarellic acid compound isolated therefrom or pharmaceutically acceptable salt thereof of the present invention leads to loss of cell adhesion to reduce cancer cell proliferation and exhibits the effect of inducing cell death in cancer cells expressing a tumor-associated antigen L6 or a homolog thereof, thereby being used for preventing and treating cancer diseases due to a tumor-associated antigen L6 or a homolog thereof.
Type:
Application
Filed:
November 25, 2009
Publication date:
April 1, 2010
Applicant:
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventors:
Hyeong-Kyu Lee, Sei-Ryang Oh, Kyungseop Ahn, Joongku Lee, Sangku Lee, Ho-Jae Lee, Doo-Young Kim, Jung-Hee Kim, Eun-Ah Kim, Soon-Ja Choi, Soo Hyun Kim, Jung Weon Lee, Su-Yong Choi
Abstract: Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases.
Abstract: The present invention is directed to novel formulations and methods for the improved delivery and administration of hydrophobic therapeutic compounds that are substantially insoluble and/or susceptible to precipitation in aqueous solution at physiological pH, including, e.g., growth and differentiation factor-5 and related proteins. Many therapeutic compounds are hydrophobic at physiological pH levels.
Type:
Application
Filed:
October 23, 2007
Publication date:
March 25, 2010
Applicants:
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung von Pharmaka mbH, Healthpartners Research Foundation
Inventors:
Leah R. Hansom, William H. Frey, II, John D. Hoekman, Jens Pohl
Abstract: A method is described for treating or preventing a bone loss disease or a bone loss disorder in a mammalian subject or reducing the incidence of a bone loss disease or a bone loss disorder or alleviating the symptoms thereof. The method includes providing to the mammalian subject at least one treatment regimen including at least one follicle-stimulating hormone modulator configured to and in an amount sufficient to reduce bioactivity or bioavailability of follicle-stimulating hormone in the mammalian subject.
Type:
Application
Filed:
July 27, 2009
Publication date:
March 11, 2010
Inventors:
Muriel Y. Ishikawa, Lowell L. Wood, JR.
Abstract: A method of and product for reducing the undesirable effects of allergic rhinitis by applying a formulation to a person's nasal region or nostrils. The formulation creates a barrier that prevents airborne allergens from contacting nasal mucous membranes, and at the same time, electrostatically repels or attracts and captures the particulate allergens, and changes their shapes so as to mitigate the effects of allergic rhinitis. The formulation may be made more effective by the addition of an anti-histamine compound.
Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.
Type:
Application
Filed:
June 25, 2009
Publication date:
March 4, 2010
Applicant:
STIEFEL RESEARCH AUSTRALIA PTY LTD
Inventors:
Maria Graziella Larm, Ronald Harding, Michael Johnston, Albert Zorko Abram, Prema Vijayakumar, Phoebe Sun
Abstract: A perfume-containing PIT emulsion which is suited to contribute to an excellent and long-lasting scenting of textiles during the use of a dryer. The PIT emulsion is simple for the user to handle and allows the user to better control the user's individual scent experience during the handling of textiles. The PIT emulsions can also be used for aroma therapy purposes and for the scenting of rooms. In addition, a kit made of detergents and the perfume-containing PIT emulsion, which enables the user to obtain optimal laundry scenting results.
Type:
Application
Filed:
November 5, 2009
Publication date:
February 25, 2010
Applicant:
Henkel AG & Co., KGaA
Inventors:
Gert-Lothar Striepling, Andreas Bauer, Matthias Hloucha, Thomas Gerke, Gerard Veldman
Abstract: A pharmaceutical composition for treating a lip condition. The pharmaceutical composition includes a therapeutically effective amount of a corticosteroid, or a physiologically acceptable salt of the corticosteroid, and a physiologically acceptable carrier In the composition, the corticosteroid does not include hydrocortisone. Also provided is a method of using the composition to treat a lip condition such as inflammation or infection.
Abstract: One aspect of the present invention relates to a granulate having a volume weighted mean diameter of 1-200 m and containing: at least 0.1 wt. % of a pharmaceutically active substance; at least 10 wt. % of emulsifier 0-89.9 wt. % of a water-dispersible saccharide; the combination of the pharmaceutically active substance, the emulsifier and the water-dispersible saccharide together representing at least 60 wt. % of the granulate; wherein the granulate is monophasic or wherein the granulate comprises a dispersed phase containing the pharmaceutically active substance, said dispersed phase having a volume weighted mean diameter of less than 300 nm. Another aspect of the invention relates to a process for the preparation of said granulate containing a pharmaceutically active substance, which process employs.
Type:
Application
Filed:
September 14, 2007
Publication date:
February 11, 2010
Inventors:
Hubert Clemens Pellikaan, Pieter Sebastlaan Vermeulen, Johannes Caspar Mathias Elizabeth Bender, Maria Vanesa Fernandez Cid
Abstract: To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance, or improve the pathosis, the present invention provides an agent or a food or drink which contains a compound having a cyclolanostane skeleton, or an organic solvent extract, a hot water extract of a plant of the family Liliaceae or Gramineae, or a fraction thereof which contains the compound as an active ingredient.
Abstract: Novel polyallylamine (PAA) based graft polymers are provided, including groups such as cholesteryl, cetyl, palmitoyl, which are adapted to deliver an entity that is normally of poor solubility in an aqueous medium, said entity being such as a drug, peptide, protein, or polynucleotide that is releasably contained within the said polymer, the resulting complex being of nanoparticle range sizes with a Tg of less than 37° C. and deliverable in aqueous media as micelles of typically 100 to 500 nm in hydrodynamic diameter, thereby offering a delivery vehicle capable of oral or parenteral administration that protects the entity from enzymes and critical pH changes.
Abstract: An injectable hydrogel includes a hydrogel matrix based on (a) single-phase-type cross-linked biopolymer(s), characterized in that previously cross-linked biopolymer hydrogel particles are co-cross-linked with the matrix. A method of and a process for production of the above-mentioned hydrogel are also disclosed.
Abstract: A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on steroid hormone levels prior to disease diagnosis in the subject and on current steroid hormone levels in the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological pre-disease levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject.
Type:
Application
Filed:
October 23, 2008
Publication date:
January 28, 2010
Inventors:
Roderick A. Hyde, Muriel Y. Ishikawa, Dennis J. Rivet, Elizabeth A. Sweeney, Lowell L. Wood, JR., Victoria Y.H. Wood
Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on said substrate, wherein said coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within said coating and on said substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of said medical device in the body of said subject a portion of said pharmaceutical agent and/or active biological agent is delivered at said intervention site along with at least a portion of said polymer and/or a at least a portion of said pharmaceutical carrying agents.
Type:
Application
Filed:
July 16, 2009
Publication date:
January 21, 2010
Applicant:
MICELL TECHNOLOGIES, INC.
Inventors:
James B. McClain, Douglas Taylor, John Neet